Product Theater: Johnson & Johnson - When Antidepressant Response Is Insufficient: Addressing Unmet Needs in Major Depressive Disorder
Tuesday, December 8, 2026, – (America/New_York)
Product Theater
This session highlights what is at stake when unresolved symptoms persist in patients with major depressive disorder despite antidepressant treatment. We will follow a clinical scenario involving a patient with persistent symptoms and review the evidence supporting adjunctive atypical antipsychotic therapy. Key clinical trial data relevant to adjunctive treatment decisions in psychiatry will be discussed.
The consultant is a paid speaker for Johnson & Johnson. The speaker is presenting on behalf of Johnson & Johnson and must present information in compliance with FDA requirements applicable to Johnson & Johnson. CME credits are not available.
Full Prescribing Information, including Boxed WARNINGS for CAPLYTA
© Johnson & Johnson and its affiliates 2026
11/2026 cp-601039v1
Speakers
-
FNP, PMHNP, DNP, Crestwood Behavioral Health San Francisco, CA